T 22

Drug Profile

T 22

Latest Information Update: 26 Feb 2008

Price : $50

At a glance

  • Originator Seikagaku Corporation
  • Class Antivirals; Peptides
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 24 Feb 2000 A study has been added to the antimicrobial activities section
  • 31 Jan 1995 A study has been added to the antimicrobial activity section
  • 01 Dec 1994 Preclinical development for HIV infections treatment in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top